Cargando…

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

BACKGROUND: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donahue, Renee N., Lepone, Lauren M., Grenga, Italia, Jochems, Caroline, Fantini, Massimo, Madan, Ravi A., Heery, Christopher R., Gulley, James L., Schlom, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320726/ https://www.ncbi.nlm.nih.gov/pubmed/28239472 http://dx.doi.org/10.1186/s40425-017-0220-y

Ejemplares similares

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses
por: Grenga, Italia, et al.
Publicado: (2016)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment
por: Grenga, Italia, et al.
Publicado: (2014)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
por: Rajan, Arun, et al.
Publicado: (2019)

Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic
por: Donahue, Renee N, et al.
Publicado: (2021)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells
por: Donahue, Renee N, et al.
Publicado: (2013)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Hierarchy of human IgG recognition within the Staphylococcus aureus immunome
por: Radke, Emily E., et al.
Publicado: (2018)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Tumor vascular normalization as a strategy to potentiate effectiveness of therapeutic vaccines
por: Farsaci, Benedetto, et al.
Publicado: (2014)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways
por: Gyurján, István, et al.
Publicado: (2019)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

The Immunome of Colon Cancer: Functional In Silico Analysis of Antigenic Proteins Deduced from IgG Microarray Profiling
por: Luna Coronell, Johana A., et al.
Publicado: (2018)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

MONOCLONAL PRODUCTION OF BOTH IgM AND IgG1 ANTIHAPTEN ANTIBODY
por: Press, Joan L., et al.
Publicado: (1973)

IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy
por: Smith, Heath A., et al.
Publicado: (2011)

Immunome Research
por: Petrovsky, Nikolai
Publicado: (2005)

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
por: Fallon, Jonathan K., et al.
Publicado: (2017)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Immunome Knowledge Base (IKB): An integrated service for immunome research
por: Ortutay, Csaba, et al.
Publicado: (2009)

Glomerulonephritis with monoclonal IgG deposits
por: Gandhi, K., et al.
Publicado: (2015)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
por: Juliá, Estefanía Paula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n7ob8lbv742u6bh4dum7obisvj